Construction of Escherichia Coli Strains with Chromosomally Integrated Expression Cassettes for the Synthesis of 2'-fucosyllactose
Overview
Microbiology
Affiliations
Background: The trisaccharide 2'-fucosyllactose (2'-FL) is one of the most abundant oligosaccharides found in human milk. Due to its prebiotic and anti-infective properties, 2'-FL is discussed as nutritional additive for infant formula. Besides chemical synthesis and extraction from human milk, 2'-FL can be produced enzymatically in vitro and in vivo. The most promising approach for a large-scale formation of 2'-FL is the whole cell biosynthesis in Escherichia coli by intracellular synthesis of GDP-L-fucose and subsequent fucosylation of lactose with an appropriate α1,2-fucosyltransferase. Even though whole cell approaches have been demonstrated for the synthesis of 2'-FL, further improvements of the engineered E. coli host are required to increase product yields. Furthermore, an antibiotic-free method of whole cell synthesis of 2'-FL is desirable to simplify product purification and to avoid traces of antibiotics in a product with nutritional purpose.
Results: Here we report the construction of the first selection marker-free E. coli strain that produces 2'-FL from lactose and glycerol. To construct this strain, recombinant genes of the de novo synthesis pathway for GDP-L-fucose as well as the gene for the H. pylori fucosyltransferase futC were integrated into the chromosome of E. coli JM109 by using the λ-Red recombineering technique. Strains carrying additional copies of the futC gene and/or the gene fkp (from Bacteroides fragilis) for an additional salvage pathway for GDP-L-fucose production were used and shown to further improve production of 2'-FL in shake flask experiments. An increase of the intracellular GDP-L-fucose concentration by expression of fkp gene as well as an additional copy of the futC gene lead to an enhanced formation of 2'-FL. Using an improved production strain, feasibility of large scale 2'-FL production was demonstrated in an antibiotic-free fed-batch fermentation (13 l) with a final 2'-FL concentration of 20.28 ± 0.83 g l(-1) and a space-time-yield of 0.57 g l(-1) h(-1).
Conclusions: By chromosomal integration of recombinant genes, altering the copy number of these genes and analysis of 2'-FL and intracellular GDP-L-fucose levels, we were able to construct and improve the first selection marker-free E. coli strain which is capable to produce 2'-FL without the use of expression plasmids. Analysis of intracellular GDP-L-fucose levels identified the de novo synthesis pathway of GDP-L-fucose as one bottleneck in 2'-FL production. In antibiotic-free fed-batch fermentation with an improved strain, scale-up of 2'-FL could be demonstrated.
Recent advances in the science of human milk oligosaccharides.
Urashima T, Ajisaka K, Ujihara T, Nakazaki E BBA Adv. 2025; 7:100136.
PMID: 39991261 PMC: 11847054. DOI: 10.1016/j.bbadva.2024.100136.
Duman H, Bechelany M, Karav S Nutrients. 2025; 17(1.
PMID: 39796552 PMC: 11723173. DOI: 10.3390/nu17010118.
Metabolic engineering of Priestia megaterium for 2'-fucosyllactose production.
Park B, Yoon J, Lee J, Cho S, Choi Y, Cho B Microb Cell Fact. 2025; 24(1):2.
PMID: 39754105 PMC: 11699682. DOI: 10.1186/s12934-024-02620-w.
Guide RNA structure design enables combinatorial CRISPRa programs for biosynthetic profiling.
Fontana J, Sparkman-Yager D, Faulkner I, Cardiff R, Kiattisewee C, Walls A Nat Commun. 2024; 15(1):6341.
PMID: 39068154 PMC: 11283517. DOI: 10.1038/s41467-024-50528-1.
You R, Wang L, Hu M, Tao Y Microb Cell Fact. 2024; 23(1):38.
PMID: 38303005 PMC: 10835893. DOI: 10.1186/s12934-024-02312-5.